Latest news

View all

Global report – February 9, 2026

Innovent and Lilly in strategic collaboration

Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company (“Lilly”) to advance novel medicines in oncology and immunology.

Science News – February 9, 2026

Nordic registers reveal COVID‑19’s impact on cancer survival

A 2026 population‑based cohort study covering Denmark, Finland, Iceland, Norway and Sweden analysed 1‑year relative survival and excess mortality in cancer patients diagnosed during March–December 2020 versus expectations from 2011–2019.

Biotech article – February 5, 2026

Denmark’s regulatory stance seen as an edge for biotechs

Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.

Event Highlights – February 4, 2026

Cancer Crosslinks at 18: Mapping and mastering complexity in modern oncology

When Cancer Crosslinks took place in Oslo on January 22, it marked the meeting’s 18th anniversary. It’s “really coming of age,” jokes Jutta Heix, the Head of International Affairs at Oslo Cancer Cluster, which organizes the meeting.

Biotech Business – February 4, 2026

Cereno Scientific broadens development focus for CS014

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Collaboration – February 4, 2026

New Swedish framework to ease industry–healthcare collaboration

Sweden’s updated “samverkansregler” governing collaboration between healthcare and industry took effect on 1 February 2026, following a revised national agreement between SKR (Swedish Association of Local Authorities and Regions) and the trade organisations Lif, Swedish Medtech, SwedenBIO and Swedish Labtech.

Opinion & debate

Clinical Trials

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Clinical Trials – January 27, 2026

Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study

The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).

Clinical Trials – January 27, 2026

DexTech Medical’s myeloma study, completed at the end of February

The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Clinical Trials – January 8, 2026

Herantis Pharma reports encouraging data from Phase 1b trial

Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Nobel Prize Laureate – December 20, 2018

Frances H. Arnold: Better than Nature herself

Read Chris Tachibana’s exclusive interview with Frances H. Arnold, a Nobel Laureate in Chemistry 2018, and learn more about her bold approaches to optimizing enzymes for society’s benefit.

Sponsored content

Vaisala environmental monitoring helps VisionGift restore sight and renew lives

By delivering precise environmental monitoring, Vaisala helps VisionGift safeguard donated eye tissue, ensure regulatory compliance, and reduce waste. Continuous data, remote alarms, and easy reporting support quality-driven operations that protect transplant outcomes and enable people worldwide to receive sight safely.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • The Nobel Prize: Exclusive interviews with Mary Brunkow, Fred Ramsdell, Shimon Sakaguchi, and Omar Yaghi. Deepen your knowledge on Tregs, MOFs, and quantum technology.
  • Hot topics: What are the effects of climate change on health and how far have we come within organ and tissue repair?
  • Business: Learn more about a career as Chief Financial Officer and the next generation of entrepreneurs in Iceland. Exclusive interview with Leif Johansson, former Chairman of AstraZeneca.
Subscribe now

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.